Rsearchers and clinicians are now exploring new tools, such
as whole-genome sequencing and RNA analysis, developing better
techniques to analyze sequence data, and finding ways to get patients
with the same diseases connected faster. This effort is making rare
disease diagnosis likely to experience another revolution in the next
decade.
Exome explosion
About 15
years ago, Kliegman and his colleagues started noticing a huge unmet
need at Children’s Hospital of Wisconsin. Families would end up there
after years of searching for a diagnosis, and there was no system in
place to settle their cases. Then chair of the pediatrics department at
the Medical College of Wisconsin (MCW), Children’s Hospital’s academic
partner, Kliegman began bringing together specialists to discuss
undiagnosed cases in detail. But the team wasn’t galvanized until it
came up against the case of Nic Volker, a young boy with severe
inflammatory bowel disease. By the time Volker turned four, his
intestines were dotted with holes, he’d had a colostomy, and he mainly
ate through a feeding tube. The hospital’s gastrointestinal specialist
couldn’t make sense of the disease, leaving Volker’s doctors with no
options beyond treating his symptoms.
In 2009, at the
request of Volker’s pediatrician, a team at MCW sequenced the boy’s
exome. The $75,000 bill was covered by funds raised by Howard Jacob, the
founding director of MCW’s genetics center, who hadn’t expected to
implement exome sequencing there for at least another five years.
Analysis of Volker’s genetic data picked up more than 16,000 gene
variants, and four months of sifting through those variants revealed
that a mutation in X-linked inhibitor of apoptosis protein (XIAP), a
gene on the long arm of the X chromosome, was the likely culprit behind
his illness.1
XIAP mutations were already associated with X-linked
lymphoproliferative disease, an immunodeficiency disorder that leaves
boys unable to fight off Epstein-Barr virus. Because the gene only
affects immune cells, a cord blood transplant to replace Volker’s immune
cell progenitors was enough to essentially cure him, says Kliegman. The
case became nationally renowned as the first time DNA sequencing saved a
patient’s life.
That was one of those—Robert Kliegman
eureka moments.
Children's Hospital of Wisconsin
In a paper describing the research, the Wisconsin team noted that a
thorough study of the available medical literature turned up a list of
more than 2,000 gene variants that could have been responsible for
Volker’s condition on the basis of his symptoms alone, and XIAP wasn’t
on it. The boy’s case “was profound for all of the people in the
hospital,” says Kliegman. “That was one of those eureka moments.” The
experience led to a shift in the mindset of the hospital’s board, and
now genetic sequencing is a cornerstone of the center’s diagnostic
approach. By 2014, the MCW’s Human and Molecular Genetics Center (now
the Genomic Sciences and Precision Medicine Center) was sequencing more
than 700 patients per year.